Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
| Title: | Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
|---|---|
| Authors: | McCarthy EM; Sutton E; Nesbit S; White J; Parker B; Jayne D; Griffiths B; Isenberg WA; Rahman A; Gordon C; D'Cruz DP; Rhodes B; Lanyon P; Vital EM; Yee C-S; Edwards CJ; Teh L-S; Akil M; McHugh NJ; Zoma A; Bruce IN; Gordon P; Young-Min S; Stevens R; Prabu A; Batley M; Gendi N; Dasgupta B; Khamashta M; Hewins P; Stratton RJ; Chan A; De Lord D; King J; Dubey S; O'Riordan E; Shaffu S; Laversuch C; Sheeran TP; Vermaak E; Erb N; Pyne D; Jeffrey R; Youssef H; Al-Allaf W; Regan M; Kaul A |
| Source: | Rheumatology , 1 March 2018 |
| Publisher Information: | Oxford University Press |
| Publication Year: | 2018 |
| Collection: | Newcastle University Library ePrints Service |
| Description: | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Objectives. To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use. Methods. Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to41 B score with no new A/B scores in other organ systems at 6 months. Results. Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to September 2015, most commonly RTX (n = 261). Two hundred and fifty (93%) patients were taking glucocorticoids at baseline at a median [interquartile range (IQR)] oral dose of 10mg (5-20 mg) daily. Response rates at 6 months were available for 68% of patients. The median (IQR) BILAG score was 15 (10-23) at baseline and 3 (2-12) at 6 months (P |
| Document Type: | article in journal/newspaper |
| Language: | unknown |
| Relation: | https://eprints.ncl.ac.uk/246908 |
| Availability: | https://eprints.ncl.ac.uk/246908 |
| Accession Number: | edsbas.889BA4C4 |
| Database: | BASE |